Recent advances towards tuberculosis control: Vaccines and biomarkers

Journal of Internal Medicine

Volumn 275, Issue 5, 2014, Pages 467-480

  Weiner, J ^a   Kaufmann, S H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

Bacille Calmette Gu rin; Biomarker; Biosignature; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; EPITOPE; T LYMPHOCYTE ANTIGEN; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; DEFENSE MECHANISM; GENE EXPRESSION; GRANULOMA; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; MACROPHAGE ACTIVATION; MONONUCLEAR PHAGOCYTE; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM INDICUS PRANII; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; NONHUMAN; PATHOGENICITY; POST EXPOSURE PROPHYLAXIS; PREDICTIVE VALUE; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TREATMENT OUTCOME; TUBERCULOSIS CONTROL;

BACILLE CALMETTE-GUÉRIN; BIOMARKER; BIOSIGNATURE; TUBERCULOSIS; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, BACTERIAL; BCG VACCINE; BIOLOGICAL MARKERS; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; MODELS, IMMUNOLOGICAL; TECHNOLOGY, PHARMACEUTICAL; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84897583030     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12212     Document Type: Review

References (87)

1. Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011; 473: 463-9.
2. WHO. Global Tuberculosis Report 2013. Geneva: WHO Press, 2013.
3. UNAIDS. Global Report UNAIDS report on the global AIDS epidemic 2013. Geneva: WHO, 2013.
4. WHO. World Malaria Report 2012: WHO Global Malaria Programme. Geneva: WHO, 2012.
5. Kaufmann SHE. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 2011; 11: 633-40.
6. Kaufmann SHE. Tuberculosis vaccines: time to think about the next generation. Semin Immunol 2013; 25: 172-81.
7. Kaufmann SHE. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010; 33: 567-77.
8. Gengenbacher M, Kaufmann SHE. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 2012; 36: 514-32.
9. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011; 378: 57-72.
10. Collins HL, Kaufmann SHE. The many faces of host responses to tuberculosis. Immunology 2001; 103: 1-9.
11. Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012; 12: 581-91.
12. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol 2013; 31: 475-527.
13. Houk VN. Spread of tuberculosis via recirculated air in a naval vessel: the Byrd study. Ann N Y Acad Sci 1980; 353: 10-24.
14. Kline SE, Hedemark LL, Davies SF. Outbreak of tuberculosis among regular patrons of a neighborhood bar. N Engl J Med 1995; 333: 222-7.
15. Mahan CS, Zalwango S, Thiel BA et al. Innate and adaptive immune responses during acute M. tuberculosis infection in adult household contacts in Kampala, Uganda. Am J Trop Med Hyg 2012; 86: 690-7.
16. Moore KW, de Waal MR, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
17. Cruz A, Fraga AG, Fountain JJ et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010; 207: 1609-16.
18. Khader SA, Bell GK, Pearl JE et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4(+) T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8: 369-77.
19. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517.
20. Woodworth JS, Behar SM. Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity. Crit Rev Immunol 2006; 26: 317-52.
21. Lewinsohn DA, Gold MC, Lewinsohn DM. Views of immunology: effector T cells. Immunol Rev 2011; 240: 25-39.
22. Stenger S, Hanson DA, Teitelbaum R et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282: 121-5.
23. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-50.
24. Weinberg JB, Misukonis MA, Shami PJ et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995; 86: 1184-95.
25. Fabri M, Stenger S, Shin DM et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 2011; 3: 104ra102.
26. Bermudez LE, Young LS. Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J Leukoc Biol 1990; 48: 67-73.
27. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-3.
28. Barry CE III, Boshoff HI, Dartois V et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7: 845-55.
29. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009; 17: 183-8.
30. Maglione PJ, Chan J. How B cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol 2009; 39: 676-86.
31. Comas I, Chakravartti J, Small PM et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010; 42: 498-503.
32. Aagaard CS, Hoang TT, Vingsbo-Lundberg C, Dietrich J, Andersen P. Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immunol 2009; 183: 2659-68.
33. Brennan MJ, Delogu G. The PE multigene family: a 'molecular mantra' for mycobacteria. Trends Microbiol 2002; 10: 246-9.
34. Talarico S, Cave MD, Foxman B et al. Association of Mycobacterium tuberculosis PE PGRS33 polymorphism with clinical and epidemiological characteristics. Tuberculosis (Edinb) 2007; 87: 338-46.
35. Jeffares DC, Pain A, Berry A et al. Genome variation and evolution of the malaria parasite Plasmodium falciparum. Nat Genet 2007; 39: 120-5.
36. Kawashima Y, Pfafferott K, Frater J et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009; 458: 641-5.
37. Calmette A, Guérin C, Boquet A, Négre L. La vaccination préventive contre la tuberculose par le "BCG". Paris: Masson, 1927.
38. Hesseling AC, Marais BJ, Gie RP et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007; 25: 14-8.
39. Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271: 698-702.
40. Benn CS, Netea MG, Selin LK, Aaby P. A small jab - a big effect: nonspecific immunomodulation by vaccines. Trends Immunol 2013; 34: 431-9.
41. Tameris MD, Hatherill M, Landry BS et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381: 1021-8.
42. Frick M. The TB Vaccines Pipeline: Where are We Going, Where Have We Been? [2013 Pipeline Report]. London: HIV i-Base and Treatment Action Group, 2013; 263-83.
43. Smaill F, Jeyanathan M, Smieja M et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 2013; 5: 205ra134.
44. Christensen D, Foged C, Rosenkrands I et al. CAF01 liposomes as a mucosal vaccine adjuvant: in vitro and in vivo investigations. Int J Pharm 2010; 390: 19-24.
45. Lingnau K, Riedl K, von Gabain A. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev Vaccines 2007; 6: 741-6.
46. van Dissel JT, Arend SM, Prins C et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010; 28: 3571-81.
47. Aagaard C, Hoang T, Dietrich J et al. A multistage tuberculosis vaccine that confers efficient protection pre- and post-exposure. Nat Med 2011; 17: 189-94.
48. Montoya J, Solon JA, Cunanan SR et al. A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-Positive Adults. J Clin Immunol 2013; 33: 1360-75.
49. Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O et al. Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults. Clin Vaccine Immunol 2010; 17: 1763-71.
50. Bertholet S, Ireton GC, Ordway DJ et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010; 2: 53ra74.
51. von Reyn CF, Mtei L, Arbeit RD et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24: 675-85.
52. Kaufmann SHE, Gengenbacher M. Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol 2012; 23: 900-7.
53. Grode L, Seiler P, Baumann S et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 2005; 115: 2472-9.
54. Grode L, Ganoza CA, Brohm C, Weiner J3, Eisele B, Kaufmann SHE. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clnical trial. Vaccine 2013; 31: 1340-8.
55. Arbues A, Aguilo JI, Gonzalo-Asensio J et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 2013; 31: 4867-73.
56. Prabowo SA, Groschel MI, Schmidt ED et al. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 2013; 202: 95-104.
57. Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 2006; 86: 273-89.
58. de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev 2010; 1: CD001166.
59. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
60. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013; 368: 745-55.
61. Weiner J III, Parida SK, Maertzdorf J et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS ONE 2012; 7: e40221.
62. Weiner J, Maertzdorf J, Kaufmann SHE. The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis. Ann N Y Acad Sci 2013; 1283: 22-9.
63. Rodgers JL, Nicewander WA, Toothaker L. Linearly independent, orthogonal, and uncorrelated variables. Am Stat 1984; 38: 133-4.
64. Gibot S, Bene MC, Noel R et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012; 186: 65-71.
65. Furman D, Jojic V, Kidd B et al. Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol 2013; 9: 659.
66. Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc Series B Stat Methodol 2005; 67: 301-20.
67. Berry MP, Graham CM, McNab FW et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-7.
68. Jacobsen M, Repsilber D, Gutschmidt A et al. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med (Berl) 2007; 85: 613-21.
69. Maertzdorf J, Weiner J III, Mollenkopf HJ et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci USA 2012; 109: 7853-8.
70. Ottenhoff TH, Dass RH, Yang N et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS ONE 2012; 7: e45839.
71. Koth LL, Solberg OD, Peng JC, Bhakta NR, Nguyen CP, Woodruff PG. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med 2011; 184: 1153-63.
72. Bloom CI, Graham CM, Berry MP et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS ONE 2013; 8: e70630.
73. Kaforou M, Wright VJ, Oni T et al. Detection of tuberculosis in HIV-infected and -uninfected African adults using whole blood RNA expression signatures: a case-control study. PLoS Med 2013; 10: e1001538.
74. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011; 11: 343-54.
75. Agranoff D, Fernandez-Reyes D, Papadopoulos MC et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006; 368: 1012-21.
76. Maertzdorf J, Weiner J III, Kaufmann SHE. Enabling biomarkers for tuberculosis control. Int J Tuberc Lung Dis 2012; 16: 1140-8.
77. Herra CM, Keane CT, Whelan A. Increased expression of Fc gamma receptors on neutrophils and monocytes may reflect ongoing bacterial infection. J Med Microbiol 1996; 44: 135-40.
78. De Groote MA, Nahid P, Jarlsberg L et al. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS ONE 2013; 8: e61002.
79. Prior C, Guillen-Grima F, Robles JE et al. Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer. World J Urol 2010; 28: 681-6.
80. Bloom CI, Graham CM, Berry MP et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS ONE 2012; 7: e46191.
81. Dai JJ, Lieu L, Rocke D. Dimension reduction for classification with gene expression microarray data. Stat Appl Genet Mol Biol 2006; 5: Article6.
82. Hahne F, Huber W, Gentleman R, Falcon S. Bioconductor Case Studies. New York: Springer, 2008.
83. Rousu J, Agranoff DD, Sodeinde O, Shawe-Taylor J, Fernandez-Reyes D. Biomarker discovery by sparse canonical correlation analysis of complex clinical phenotypes of tuberculosis and malaria. PLoS Comput Biol 2013; 9: e1003018.
84. Maertzdorf J, Ota M, Repsilber D et al. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS ONE 2011; 6: e26938.
85. Tarca AL, Carey VJ, Chen XW, Romero R, Draghici S. Machine learning and its applications to biology. PLoS Comput Biol 2007; 3: e116.
86. Strube MJ. SNOOP:a program for demonstrating the consequences of premature and repeated null hypothesis testing. Behav Res Methods 2006; 38: 24-7.
87. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.